Drug discount programs like the Medicaid Drug Rebate Program (“MDRP”) and 340B Drug Discount Program (“340B Program”), have been critical tools in ensuring access to prescription drugs to those who cannot afford them.
Unfortunately, as existing programs have been expanded and new ones created, the ecosystem surrounding the pharmaceutical industry, from manufacturers to payers to providers to numerous government agencies, has become more intertwined and complex, leading to noncompliance. However, there is a path forward to bring transparency and integrity to these critical programs.
Download our whitepaper to learn more.